Copyright Reports & Markets. All rights reserved.

Global and United States Cell and Gene Therapy Manufacturing Services Market Report & Forecast 2022-2028

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Cell and Gene Therapy Manufacturing Services Revenue in Cell and Gene Therapy Manufacturing Services Business (2017-2022) & (US$ Million) Introduction
    • 1.2 Global Cell and Gene Therapy Manufacturing Services Outlook 2017 VS 2022 VS 2028
      • 1.2.1 Global Cell and Gene Therapy Manufacturing Services Market Size for the Year 2017-2028
      • 1.2.2 Global Cell and Gene Therapy Manufacturing Services Market Size for the Year 2017-2028
    • 1.3 Cell and Gene Therapy Manufacturing Services Market Size, United States VS Global, 2017 VS 2022 VS 2028
      • 1.3.1 The Market Share of United States Cell and Gene Therapy Manufacturing Services in Global, 2017 VS 2022 VS 2028
      • 1.3.2 The Growth Rate of Cell and Gene Therapy Manufacturing Services Market Size, United States VS Global, 2017 VS 2022 VS 2028
    • 1.4 Cell and Gene Therapy Manufacturing Services Market Dynamics
      • 1.4.1 Cell and Gene Therapy Manufacturing Services Industry Trends
      • 1.4.2 Cell and Gene Therapy Manufacturing Services Market Drivers
      • 1.4.3 Cell and Gene Therapy Manufacturing Services Market Challenges
      • 1.4.4 Cell and Gene Therapy Manufacturing Services Market Restraints
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Cell and Gene Therapy Manufacturing Services by Type

    • 2.1 Cell and Gene Therapy Manufacturing Services Market Segment by Type
      • 2.1.1 Allogeneic
      • 2.1.2 Autologous
      • 2.1.3 Viral Vector
    • 2.2 Global Cell and Gene Therapy Manufacturing Services Market Size by Type (2017, 2022 & 2028)
    • 2.3 Global Cell and Gene Therapy Manufacturing Services Market Size by Type (2017-2028)
    • 2.4 United States Cell and Gene Therapy Manufacturing Services Market Size by Type (2017, 2022 & 2028)
    • 2.5 United States Cell and Gene Therapy Manufacturing Services Market Size by Type (2017-2028)

    3 Cell and Gene Therapy Manufacturing Services by Application

    • 3.1 Cell and Gene Therapy Manufacturing Services Market Segment by Application
      • 3.1.1 Oncology Diseases
      • 3.1.2 Cardiovascular Diseases
      • 3.1.3 Orthopedic Diseases
      • 3.1.4 Ophthalmology Diseases
      • 3.1.5 Infectious Diseases
      • 3.1.6 Others
    • 3.2 Global Cell and Gene Therapy Manufacturing Services Market Size by Application (2017, 2022 & 2028)
    • 3.3 Global Cell and Gene Therapy Manufacturing Services Market Size by Application (2017-2028)
    • 3.4 United States Cell and Gene Therapy Manufacturing Services Market Size by Application (2017, 2022 & 2028)
    • 3.5 United States Cell and Gene Therapy Manufacturing Services Market Size by Application (2017-2028)

    4 Global Cell and Gene Therapy Manufacturing Services Competitor Landscape by Company

    • 4.1 Global Cell and Gene Therapy Manufacturing Services Market Size by Company
      • 4.1.1 Top Global Cell and Gene Therapy Manufacturing Services Companies Ranked by Revenue (2021)
      • 4.1.2 Global Cell and Gene Therapy Manufacturing Services Revenue by Player (2017-2022)
    • 4.2 Global Cell and Gene Therapy Manufacturing Services Concentration Ratio (CR)
      • 4.2.1 Cell and Gene Therapy Manufacturing Services Market Concentration Ratio (CR) (2017-2022)
      • 4.2.2 Global Top 5 and Top 10 Largest Companies of Cell and Gene Therapy Manufacturing Services in 2021
      • 4.2.3 Global Cell and Gene Therapy Manufacturing Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    • 4.3 Global Cell and Gene Therapy Manufacturing Services Headquarters, Revenue in Cell and Gene Therapy Manufacturing Services Business (2017-2022) & (US$ Million) Type
      • 4.3.1 Global Cell and Gene Therapy Manufacturing Services Headquarters and Area Served
      • 4.3.2 Global Cell and Gene Therapy Manufacturing Services Companies Revenue in Cell and Gene Therapy Manufacturing Services Business (2017-2022) & (US$ Million) Type
      • 4.3.3 Date of International Companies Enter into Cell and Gene Therapy Manufacturing Services Market
    • 4.4 Companies Mergers & Acquisitions, Expansion Plans
    • 4.5 United States Cell and Gene Therapy Manufacturing Services Market Size by Company
      • 4.5.1 Top Cell and Gene Therapy Manufacturing Services Players in United States, Ranked by Revenue (2021)
      • 4.5.2 United States Cell and Gene Therapy Manufacturing Services Revenue by Players (2020, 2021 & 2022)

    5 Global Cell and Gene Therapy Manufacturing Services Market Size by Region

    • 5.1 Global Cell and Gene Therapy Manufacturing Services Market Size by Region: 2017 VS 2022 VS 2028
    • 5.2 Global Cell and Gene Therapy Manufacturing Services Market Size by Region (2017-2028)
      • 5.2.1 Global Cell and Gene Therapy Manufacturing Services Market Size by Region: 2017-2022
      • 5.2.2 Global Cell and Gene Therapy Manufacturing Services Market Size by Region (2023-2028)

    6 Segment in Region Level & Country Level

    • 6.1 North America
      • 6.1.1 North America Cell and Gene Therapy Manufacturing Services Market Size YoY Growth 2017-2028
      • 6.1.2 North America Cell and Gene Therapy Manufacturing Services Market Facts & Figures by Country (2017, 2022 & 2028)
      • 6.1.3 United States
      • 6.1.4 Canada
    • 6.2 Asia-Pacific
      • 6.2.1 Asia-Pacific Cell and Gene Therapy Manufacturing Services Market Size YoY Growth 2017-2028
      • 6.2.2 Asia-Pacific Cell and Gene Therapy Manufacturing Services Market Facts & Figures by Region (2017, 2022 & 2028)
      • 6.2.3 China
      • 6.2.4 Japan
      • 6.2.5 South Korea
      • 6.2.6 India
      • 6.2.7 Australia
      • 6.2.8 China Taiwan
      • 6.2.9 Indonesia
      • 6.2.10 Thailand
      • 6.2.11 Malaysia
    • 6.3 Europe
      • 6.3.1 Europe Cell and Gene Therapy Manufacturing Services Market Size YoY Growth 2017-2028
      • 6.3.2 Europe Cell and Gene Therapy Manufacturing Services Market Facts & Figures by Country (2017, 2022 & 2028)
      • 6.3.3 Germany
      • 6.3.4 France
      • 6.3.5 U.K.
      • 6.3.6 Italy
      • 6.3.7 Russia
    • 6.4 Latin America
      • 6.4.1 Latin America Cell and Gene Therapy Manufacturing Services Market Size YoY Growth 2017-2028
      • 6.4.2 Latin America Cell and Gene Therapy Manufacturing Services Market Facts & Figures by Country (2017, 2022 & 2028)
      • 6.4.3 Mexico
      • 6.4.4 Brazil
      • 6.4.5 Argentina
      • 6.4.6 Colombia
    • 6.5 Middle East and Africa
      • 6.5.1 Middle East and Africa Cell and Gene Therapy Manufacturing Services Market Size YoY Growth 2017-2028
      • 6.5.2 Middle East and Africa Cell and Gene Therapy Manufacturing Services Market Facts & Figures by Country (2017, 2022 & 2028)
      • 6.5.3 Turkey
      • 6.5.4 Saudi Arabia
      • 6.5.5 UAE

    7 Company Profiles

    • 7.1 Thermo Fisher Scientific
      • 7.1.1 Thermo Fisher Scientific Company Details
      • 7.1.2 Thermo Fisher Scientific Business Overview
      • 7.1.3 Thermo Fisher Scientific Cell and Gene Therapy Manufacturing Services Introduction
      • 7.1.4 Thermo Fisher Scientific Revenue in Cell and Gene Therapy Manufacturing Services Business (2017-2022)
      • 7.1.5 Thermo Fisher Scientific Recent Development
    • 7.2 Merck KGaA
      • 7.2.1 Merck KGaA Company Details
      • 7.2.2 Merck KGaA Business Overview
      • 7.2.3 Merck KGaA Cell and Gene Therapy Manufacturing Services Introduction
      • 7.2.4 Merck KGaA Revenue in Cell and Gene Therapy Manufacturing Services Business (2017-2022)
      • 7.2.5 Merck KGaA Recent Development
    • 7.3 Charles River Laboratories
      • 7.3.1 Charles River Laboratories Company Details
      • 7.3.2 Charles River Laboratories Business Overview
      • 7.3.3 Charles River Laboratories Cell and Gene Therapy Manufacturing Services Introduction
      • 7.3.4 Charles River Laboratories Revenue in Cell and Gene Therapy Manufacturing Services Business (2017-2022)
      • 7.3.5 Charles River Laboratories Recent Development
    • 7.4 Lonza
      • 7.4.1 Lonza Company Details
      • 7.4.2 Lonza Business Overview
      • 7.4.3 Lonza Cell and Gene Therapy Manufacturing Services Introduction
      • 7.4.4 Lonza Revenue in Cell and Gene Therapy Manufacturing Services Business (2017-2022)
      • 7.4.5 Lonza Recent Development
    • 7.5 Catalent
      • 7.5.1 Catalent Company Details
      • 7.5.2 Catalent Business Overview
      • 7.5.3 Catalent Cell and Gene Therapy Manufacturing Services Introduction
      • 7.5.4 Catalent Revenue in Cell and Gene Therapy Manufacturing Services Business (2017-2022)
      • 7.5.5 Catalent Recent Development
    • 7.6 WuXi AppTec
      • 7.6.1 WuXi AppTec Company Details
      • 7.6.2 WuXi AppTec Business Overview
      • 7.6.3 WuXi AppTec Cell and Gene Therapy Manufacturing Services Introduction
      • 7.6.4 WuXi AppTec Revenue in Cell and Gene Therapy Manufacturing Services Business (2017-2022)
      • 7.6.5 WuXi AppTec Recent Development
    • 7.7 Takara Bio Inc
      • 7.7.1 Takara Bio Inc Company Details
      • 7.7.2 Takara Bio Inc Business Overview
      • 7.7.3 Takara Bio Inc Cell and Gene Therapy Manufacturing Services Introduction
      • 7.7.4 Takara Bio Inc Revenue in Cell and Gene Therapy Manufacturing Services Business (2017-2022)
      • 7.7.5 Takara Bio Inc Recent Development
    • 7.8 Nikon Corporation
      • 7.8.1 Nikon Corporation Company Details
      • 7.8.2 Nikon Corporation Business Overview
      • 7.8.3 Nikon Corporation Cell and Gene Therapy Manufacturing Services Introduction
      • 7.8.4 Nikon Corporation Revenue in Cell and Gene Therapy Manufacturing Services Business (2017-2022)
      • 7.8.5 Nikon Corporation Recent Development
    • 7.9 FUJIFILM Holdings Corporation
      • 7.9.1 FUJIFILM Holdings Corporation Company Details
      • 7.9.2 FUJIFILM Holdings Corporation Business Overview
      • 7.9.3 FUJIFILM Holdings Corporation Cell and Gene Therapy Manufacturing Services Introduction
      • 7.9.4 FUJIFILM Holdings Corporation Revenue in Cell and Gene Therapy Manufacturing Services Business (2017-2022)
      • 7.9.5 FUJIFILM Holdings Corporation Recent Development
    • 7.10 F. Hoffmann-La Roche
      • 7.10.1 F. Hoffmann-La Roche Company Details
      • 7.10.2 F. Hoffmann-La Roche Business Overview
      • 7.10.3 F. Hoffmann-La Roche Cell and Gene Therapy Manufacturing Services Introduction
      • 7.10.4 F. Hoffmann-La Roche Revenue in Cell and Gene Therapy Manufacturing Services Business (2017-2022)
      • 7.10.5 F. Hoffmann-La Roche Recent Development
    • 7.11 Oxford Biomedica Plc
      • 7.11.1 Oxford Biomedica Plc Company Details
      • 7.11.2 Oxford Biomedica Plc Business Overview
      • 7.11.3 Oxford Biomedica Plc Cell and Gene Therapy Manufacturing Services Introduction
      • 7.11.4 Oxford Biomedica Plc Revenue in Cell and Gene Therapy Manufacturing Services Business (2017-2022)
      • 7.11.5 Oxford Biomedica Plc Recent Development
    • 7.12 Cell and Gene Therapy Catapult
      • 7.12.1 Cell and Gene Therapy Catapult Company Details
      • 7.12.2 Cell and Gene Therapy Catapult Business Overview
      • 7.12.3 Cell and Gene Therapy Catapult Cell and Gene Therapy Manufacturing Services Introduction
      • 7.12.4 Cell and Gene Therapy Catapult Revenue in Cell and Gene Therapy Manufacturing Services Business (2017-2022)
      • 7.12.5 Cell and Gene Therapy Catapult Recent Development
    • 7.13 The Discovery Labs LLC
      • 7.13.1 The Discovery Labs LLC Company Details
      • 7.13.2 The Discovery Labs LLC Business Overview
      • 7.13.3 The Discovery Labs LLC Cell and Gene Therapy Manufacturing Services Introduction
      • 7.13.4 The Discovery Labs LLC Revenue in Cell and Gene Therapy Manufacturing Services Business (2017-2022)
      • 7.13.5 The Discovery Labs LLC Recent Development
    • 7.14 RoslinCT
      • 7.14.1 RoslinCT Company Details
      • 7.14.2 RoslinCT Business Overview
      • 7.14.3 RoslinCT Cell and Gene Therapy Manufacturing Services Introduction
      • 7.14.4 RoslinCT Revenue in Cell and Gene Therapy Manufacturing Services Business (2017-2022)
      • 7.14.5 RoslinCT Recent Development
    • 7.15 JRS PHARMA
      • 7.15.1 JRS PHARMA Company Details
      • 7.15.2 JRS PHARMA Business Overview
      • 7.15.3 JRS PHARMA Cell and Gene Therapy Manufacturing Services Introduction
      • 7.15.4 JRS PHARMA Revenue in Cell and Gene Therapy Manufacturing Services Business (2017-2022)
      • 7.15.5 JRS PHARMA Recent Development
    • 7.16 FinVector
      • 7.16.1 FinVector Company Details
      • 7.16.2 FinVector Business Overview
      • 7.16.3 FinVector Cell and Gene Therapy Manufacturing Services Introduction
      • 7.16.4 FinVector Revenue in Cell and Gene Therapy Manufacturing Services Business (2017-2022)
      • 7.16.5 FinVector Recent Development
    • 7.17 ABL
      • 7.17.1 ABL Company Details
      • 7.17.2 ABL Business Overview
      • 7.17.3 ABL Cell and Gene Therapy Manufacturing Services Introduction
      • 7.17.4 ABL Revenue in Cell and Gene Therapy Manufacturing Services Business (2017-2022)
      • 7.17.5 ABL Recent Development
    • 7.18 Resilience
      • 7.18.1 Resilience Company Details
      • 7.18.2 Resilience Business Overview
      • 7.18.3 Resilience Cell and Gene Therapy Manufacturing Services Introduction
      • 7.18.4 Resilience Revenue in Cell and Gene Therapy Manufacturing Services Business (2017-2022)
      • 7.18.5 Resilience Recent Development
    • 7.19 BioCentriq
      • 7.19.1 BioCentriq Company Details
      • 7.19.2 BioCentriq Business Overview
      • 7.19.3 BioCentriq Cell and Gene Therapy Manufacturing Services Introduction
      • 7.19.4 BioCentriq Revenue in Cell and Gene Therapy Manufacturing Services Business (2017-2022)
      • 7.19.5 BioCentriq Recent Development
    • 7.20 Porton Biopharma Limited
      • 7.20.1 Porton Biopharma Limited Company Details
      • 7.20.2 Porton Biopharma Limited Business Overview
      • 7.20.3 Porton Biopharma Limited Cell and Gene Therapy Manufacturing Services Introduction
      • 7.20.4 Porton Biopharma Limited Revenue in Cell and Gene Therapy Manufacturing Services Business (2017-2022)
      • 7.20.5 Porton Biopharma Limited Recent Development
    • 7.21 Andelyn Biosciences
      • 7.21.1 Andelyn Biosciences Company Details
      • 7.21.2 Andelyn Biosciences Business Overview
      • 7.21.3 Andelyn Biosciences Cell and Gene Therapy Manufacturing Services Introduction
      • 7.21.4 Andelyn Biosciences Revenue in Cell and Gene Therapy Manufacturing Services Business (2017-2022)
      • 7.21.5 Andelyn Biosciences Recent Development
    • 7.22 Commercializing Living Therapies
      • 7.22.1 Commercializing Living Therapies Company Details
      • 7.22.2 Commercializing Living Therapies Business Overview
      • 7.22.3 Commercializing Living Therapies Cell and Gene Therapy Manufacturing Services Introduction
      • 7.22.4 Commercializing Living Therapies Revenue in Cell and Gene Therapy Manufacturing Services Business (2017-2022)
      • 7.22.5 Commercializing Living Therapies Recent Development
    • 7.23 Vibalogics
      • 7.23.1 Vibalogics Company Details
      • 7.23.2 Vibalogics Business Overview
      • 7.23.3 Vibalogics Cell and Gene Therapy Manufacturing Services Introduction
      • 7.23.4 Vibalogics Revenue in Cell and Gene Therapy Manufacturing Services Business (2017-2022)
      • 7.23.5 Vibalogics Recent Development
    • 7.24 Anemocyte Srl
      • 7.24.1 Anemocyte Srl Company Details
      • 7.24.2 Anemocyte Srl Business Overview
      • 7.24.3 Anemocyte Srl Cell and Gene Therapy Manufacturing Services Introduction
      • 7.24.4 Anemocyte Srl Revenue in Cell and Gene Therapy Manufacturing Services Business (2017-2022)
      • 7.24.5 Anemocyte Srl Recent Development
    • 7.25 ElevateBio
      • 7.25.1 ElevateBio Company Details
      • 7.25.2 ElevateBio Business Overview
      • 7.25.3 ElevateBio Cell and Gene Therapy Manufacturing Services Introduction
      • 7.25.4 ElevateBio Revenue in Cell and Gene Therapy Manufacturing Services Business (2017-2022)
      • 7.25.5 ElevateBio Recent Development

    8 Research Findings and Conclusion

      9 Appendix

      • 9.1 Research Methodology
        • 9.1.1 Methodology/Research Approach
        • 9.1.2 Data Source
      • 9.2 Author Details

      Summary:

      Gene therapy aims to treat disorders by replacing or introducing genes into cells— either inside the body (in vivo) or outside of the body (ex vivo).
      Market Analysis and Insights: Global and United States Cell and Gene Therapy Manufacturing Services Market
      This report focuses on global and United States Cell and Gene Therapy Manufacturing Services market, also covers the segmentation data of other regions in regional level and county level.
      Due to the COVID-19 pandemic, the global Cell and Gene Therapy Manufacturing Services market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Type, Allogeneic accounting for % of the Cell and Gene Therapy Manufacturing Services global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Application, Oncology Diseases was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.
      In United States the Cell and Gene Therapy Manufacturing Services market size is expected to grow from US$ million in 2021 to US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
      Global Cell and Gene Therapy Manufacturing Services Scope and Market Size
      Cell and Gene Therapy Manufacturing Services market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Cell and Gene Therapy Manufacturing Services market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
      For United States market, this report focuses on the Cell and Gene Therapy Manufacturing Services market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
      Segment by Type, the Cell and Gene Therapy Manufacturing Services market is segmented into
      By Cell Therapy
      Allogeneic
      Autologous
      Viral Vector
      By Gene Therapy
      Non-viral Vector
      Oligonucleotides
      Viral Vector
      Segment by Application, the Cell and Gene Therapy Manufacturing Services market is segmented into
      Oncology Diseases
      Cardiovascular Diseases
      Orthopedic Diseases
      Ophthalmology Diseases
      Infectious Diseases
      Others
      Regional and Country-level Analysis
      North America
      United States
      Canada
      Europe
      Germany
      France
      U.K.
      Italy
      Russia
      Asia-Pacific
      China
      Japan
      South Korea
      India
      Australia
      China Taiwan
      Indonesia
      Thailand
      Malaysia
      Latin America
      Mexico
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Turkey
      Saudi Arabia
      UAE
      Competitive Landscape and Cell and Gene Therapy Manufacturing Services Market Share Analysis
      Cell and Gene Therapy Manufacturing Services market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2017-2022. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2017-2022. Details included are company description, major business, company total revenue and the sales, revenue generated in Cell and Gene Therapy Manufacturing Services business, the date to enter into the Cell and Gene Therapy Manufacturing Services market, Revenue in Cell and Gene Therapy Manufacturing Services Business (2017-2022) & (US$ Million) introduction, recent developments, etc.
      The major vendors covered:
      Thermo Fisher Scientific
      Merck KGaA
      Charles River Laboratories
      Lonza
      Catalent
      WuXi AppTec
      Takara Bio Inc
      Nikon Corporation
      FUJIFILM Holdings Corporation
      F. Hoffmann-La Roche
      Oxford Biomedica Plc
      Cell and Gene Therapy Catapult
      The Discovery Labs LLC
      RoslinCT
      JRS PHARMA
      FinVector
      ABL
      Resilience
      BioCentriq
      Porton Biopharma Limited
      Andelyn Biosciences
      Commercializing Living Therapies
      Vibalogics
      Anemocyte Srl
      ElevateBio
      Buy now